In the National Consensus from Spain [61], ALK rearrangement testing is recommended in patients with advanced NSCLC who are negative for the EGFR mutation (all histological subtypes in non-smokers; non-squamous-cell carcinoma subtype in current or ex-smokers). This evidence concerns the gene EGFR and non-small cell lung carcinoma.